Edwards Lifesciences Swan Ganz Thermodilution Catheter, REF 131F7P (5 pack of 131F7) Product Usa...
FDA Device Recall #Z-0763-2019 — Class I — December 21, 2018
Recall Summary
| Recall Number | Z-0763-2019 |
| Classification | Class I — Serious risk |
| Date Initiated | December 21, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Edwards Lifesciences, LLC |
| Location | Irvine, CA |
| Product Type | Devices |
| Quantity | 875 units |
Product Description
Edwards Lifesciences Swan Ganz Thermodilution Catheter, REF 131F7P (5 pack of 131F7) Product Usage: The Swan-Ganz Thermodilution Catheter provides a diagnostic tool for physicians to rapidly determine hemodynamic pressures and cardiac output when used with a compatible cardiac output computer. Swan-Ganz thermodilution catheters are indicated for the assessment of a patient s hemodynamic condition through direct intra-cardiac and pulmonary artery pressure monitoring, cardiac output determination, and for infusing solutions. The distal (pulmonary artery) port also allows sampling of mixed venous blood for the assessment of oxygen transport balance and the calculation of derived parameters such as oxygen consumption, oxygen utilization coefficient, and intrapulmonary shunt fraction.
Reason for Recall
These Swan Ganz catheters have incorrect lumen assembly, which causes reversal of the lumens. If the lumens are reversed the clinician may note reverse PA and CVP pressure values and waveforms.
Distribution Pattern
Worldwide Distribution
Lot / Code Information
Lot Numbers: 61321241, 61176369, 61176374, 61311580, 61176373, 61321254
Other Recalls from Edwards Lifesciences, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2172-2026 | Class II | Edwards EVOQUE tricuspid delivery system REF:9... | Mar 27, 2026 |
| Z-2085-2025 | Class I | Brand Name: FEM-FLEXII Product Name: Femoral A... | May 14, 2025 |
| Z-2080-2025 | Class I | Brand Name: Optisite Arterial Cannula Product ... | May 14, 2025 |
| Z-2082-2025 | Class I | Brand Name: FEM-FLEX II Product Name: Femoral ... | May 14, 2025 |
| Z-2083-2025 | Class I | Brand Name: FEM-FLEX II Product Name: Femoral ... | May 14, 2025 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.